| Date | Title | Description |
| 27.07.2015 | AstraZeneca further sharpens focus through agreement with Genzyme for rare disease medicine | AstraZeneca further sharpens focus through agreement with Genzyme for rare disease medicine
27-07-2015
AstraZeneca today announced that it has entered into a definitive agreement with Genzyme to divest Caprelsa® (vandetanib), a rare disease... |
| 11.02.2015 | Voyager Therapeutics Grabs $30M Investment |
CAMBRIDGE, MA, Gene therapy company announced a major strategic collaboration and investment.
>> Click here for more funding data on Voyager Therapeutics
>> To export Voyager Therapeutics funding data to PDF and Excel, click... |
| 26.08.2013 | Are recalls preventable? 5 smart comments from a LinkedIn conversation you should be following | Alan Wu at Genzyme is one of many in the conversation to add actionable tips for preventing the kinds of mistakes that create recalls in the first place.
President of SoCal Preclinical Services Paul Stein asks how the tight medtech job mark... |
| 16.06.2011 | LabCorp offer to buy Orchid extended to July 15; FTC still reviewing deal | LabCorp‘s (NYSE:LH) deadline to buy DNA testing services firm Orchid Cellmark (NASDAQ:ORCH) has been extended to July 15, the third extension for the deal in the last month.
The Burlington, North Carolina-based diagnostics and laboratory se... |
| 06.04.2011 | DNA testing company Orchid to be acquired by LabCorp for $85M | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| 10.09.2010 | Good Start Genetics drums up $18 million | Good Start Genetics Inc. closed an $18 million Series A funding round and tapped former Exact Sciences Corp. (NSDQ:EXAS) head Don Hardison to be its president and CEO.
The Boston-based company is developing a pre-pregnancy genetic test desi... |
| 10.09.2010 | Good Start Genetics raises $18M for pre-pregnancy genetic test | “The chips that have been built typically look for those 23 mutations. The problem is that there are 1,700 mutations associated with cystic fibrosis. We sequence the entire gene,” Hardison told us. “You’re going to have a better idea if you... |
| 02.09.2009 | Akebia adds Dr. Victor Dzau, Duke Health CEO, to board of directors | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 07.05.2009 | Genzyme Offers Glimpse at Growth Engine, New Drugs for High Cholesterol, Gaucher’s | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Genzyme is getting to the point where the law of large numbers start to look really daunting. The Cambridge, MA-based biotech company has been so successful for so long, it ge... |
| 27.02.2009 | Arzeda, Maker of Designer Enzymes, Prepares to Leave UW Roots with New Leader and VC Bucks | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
One of the biggest startup ideas at the University of Washington is getting ready to leave the academic nest. Arzeda, which designs custom-built enzymes on computers that can ... |
| 23.05.2008 | Lies, Damned Lies, and Statistics: The Definitive Rundown on New England Biotech | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
It’s official: 2007 rocked for New England biotech. Whether you look at IPOs, mergers, or venture activity, the region is consistently among the nation’s leaders. And on a per... |
| 29.10.2007 | Genzyme Forges Chinese Connection to Speed Gene Therapy to World Market | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Genzyme (NASDAQ: GENZ) and China are probably the world’s biggest players in gene therapy, and now the two are working together, thanks to a deal announced last Friday around ... |
| 24.09.2007 | Alnylam and Merck Go Their Separate Ways, TransMedics Files to Go Public, ZipCar Reservation System Ready to Go Anywhere, and More | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Another week, another giant inbox full of news. Here are the highlights.
—Not long after closing one of New England’s 10 biggest second-quarter venture deals, Andover-based Tr... |
| 06.09.2007 | Another Voice Heard in the Genzyme-Bioenvision Takeover Debate: Elliot Associates is “Extremely Dissatisfied” | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Shareholders of New York-based Bioenvision (NASDAQ: BIVN) have yet to vote on Genzyme’s (NASDAQ: GENZ) much-maligned $5.60-per-share offer for the firm, but one of them is mak... |
| 20.08.2007 | Special Vote Called for on Genzyme’s Takeover Bid for Bioenvision: Is a Deal in the Works? | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Things seem to be moving again with Genzyme’s so-far-stymied attempts to take over New York-based Bioenvision (NASDAQ: BIVN). A little after four in the afternoon on Friday, B... |
| 10.08.2007 | Biotech’s double standard on biogenerics | (UPDATED: See below.)
Yesterday, the WSJ Health Blog cited a WSJ story as evidence that “biogenerics” — that is, generic versions of biotech drugs, which currently don’t exist — need to be treated with caution. Unfortunately, that post miss... |
| 03.08.2007 | Good News for Genzyme, Bad News for Boston Scientific, and all the Other News We Didn’t Get to This Week | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
The recent heat wave seems to have driven members of the local tech community into their offices rather than out to the beach, because this week has seen too many announcement... |
| 02.07.2007 | Genzyme Takeover of Bioenvision Falls Short; Company Tries New Tack | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
As our sources predicted Friday, Genzyme’s tender offer for New York-based Bioenvision has fallen far short of its goal, Genzyme confirmed this morning. However, the Cambridge... |
| 26.06.2007 | Ceregene: Catching an updraft in gene therapy | (UPDATED: See below.)
Ceregene, a San Diego biotech at work on a gene therapy for Parkinson’s disease, has so far raised $28 million in a third funding round and last week struck a development partnership with Genzyme that resulted in a $25... |
| 26.06.2007 | Applied Genetic Technologies gets $2M for gene therapy | Applied Genetic Technologies, an Alachua, Fla., gene-therapy developer, received a $2 million milestone payment from Genzyme.
The two companies are jointly developing a gene therapy for treating a form of blindness called age-related macula... |
| 18.05.2007 | Amicus Therapeutics aims for potentially disruptive $92M IPO | Amicus Therapeutics, a Cranbury, N.J., developer of drugs to treat rare genetic diseases, said it plans to raise as much as $92 million in an IPO — money that would fund its pursuit of new drugs for rare genetic diseases, a strategy could b... |
| 20.09.2005 | BTG plc reports progress on Campath(R) trials | BTG plc reports progress on Campath(R) trials
20-09-2005
BTG plc, the medical innovations company, today reports that Genzyme Corporation, BTG's licensee for Campath(R), and Schering AG have announced interim results of the Phase II trial c... |
| - | Lysosomal storage disorder treatment moving into proof-of-concept phase | A company formed to develop protein therapeutics to treat lysosomal storage diseases — rare genetic disorders that affect the metabolism of certain natural biological substances in cells — is raising $5 million in a series A financing round... |
| - | Are recalls preventable? 5 smart comments from a LinkedIn conversation you should be following | Last week, we learned Q2’13 saw a five-period spike in medical device recalls. On LinkedIn a few weeks prior, Medical Devices Group leader Joe Hage posed this question to the group: “Are recalls preventable?” The discussion that follows is ... |
| - | Akebia adds Dr. Victor Dzau, Duke Health CEO, to board of directors | CINCNNATI, Ohio — Dr. Victor Dzau, the president and CEO of the Duke University Health System, has joined the board of directors of Akebia Therapeutics.
This adds heavyweight talent to some significant fund-raising by Akebia. Last month it ... |
| - | LabCorp offer to buy Orchid extended to July 15; FTC still reviewing deal | LabCorp‘s (NYSE:LH) deadline to buy DNA testing services firm Orchid Cellmark (NASDAQ:ORCH) has been extended to July 15, the third extension for the deal in the last month.
The Burlington, North Carolina-based diagnostics and laboratory se... |
| - | Good Start Genetics raises $18M for pre-pregnancy genetic test | Good Start Genetics Inc. closed an $18 million Series A funding round, and tapped former Exact Sciences Corp. (NSDQ: EXAS) head Don Hardison to be its president and CEO.
The Boston-based company is developing a pre-pregnancy genetic test de... |
| - | DNA testing company Orchid to be acquired by LabCorp for $85M | Diagnostic technologies and genomic testing company LabCorp will buy DNA testing services company Orchid Cellmark in a deal valued at $85.4 million.
LabCorp (NYSE:LH) said that the definitive agreement calls for the Burlington, North Caroli... |